Thanks!! Gorgeous, first glance.
Man, you and BM sure came through today.
Here's the release in two parts, no fixed font for the wordy stuff, fixed font for the numbers.........
Friday November 9, 1:18 pm Eastern Time
Press Release
SOURCE: Cadus Pharmaceutical Corporation
Cadus Reports Third Quarter 2001 Results
NEW YORK, Nov. 9 /PRNewswire/ -- Cadus Pharmaceutical Corporation (OTC Bulletin
Board: KDUS - news) announced today financial results for the third quarter ended
September 30, 2001.
Revenues for the third quarter of 2001 were $0, compared to $23,470 for the same period in
2000. Net income for the third quarter of 2001 was $23,533, compared to net income of
$18,574,415 for the same period in 2000. Basic net income per share for the third quarter of
2001 was $0, compared to basic net income per share for the third quarter of 2000 of $1.41.
Revenues for the first nine months of 2001 were $100,000, compared to $723,470 for the
same period in 2000. Net income for the first nine months of 2001 was $131,714, compared
to net income of $17,603,426 for the same period in 2000. Basic net income per share for
the first nine months of 2001 was $0.01, compared to basic net income per share of $1.34
for the same period in 2000.
The net income for the third quarter and first nine months ended September 30, 2000 was
principally attributable to the reversal of the SIBIA Neurosciences, Inc. litigation judgment.
As of September 30, 2001, Cadus had 13,144,040 shares outstanding.
This press release may contain forward-looking statements that involve a number of risks and
uncertainties. Important factors that could cause actual results to differ materially from those
indicated by such forward-looking statements are set forth in the company's prospectus dated
July 17, 1996 or detailed from time to time in filings that the company makes with the
Securities and Exchange Commission. These include risks and uncertainties relating to the
company's ability to realize value from its assets, the company's ability to license its
technologies to third parties, technological uncertainties regarding the company's technology,
rapid technological change that may result in the company's technologies becoming obsolete,
an intensely competitive market, intellectual property rights and general economic conditions.
(CONT"D) |
